Registrational Study for the Treatment of HCC
关于我们
致力于发现与开发治疗癌症及其他疾病的新型、差异化疗法。 港交所代码：02256 HKEx code：02256
- 网站
-
www.abbisko.com
和誉医药的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- shanghai
- 类型
- 上市公司
- 创立
- 2016
地点
-
主要
获取路线
huanke road
515
CN，shanghai，201210
和誉医药员工
动态
-
ABSK131, a highly-selective small molecule inhibitor of PRMT5*MTA.
Abbisko Therapeutics Announces U.S. FDA IND Clearance for ABSK131, a Novel PRMT5*MTA Inhibitor
和誉医药，发布于领英
-
Abbisko's global Phase 3 MANEUVER study demonstrates the best-in-class profile of pimicotinib for treating Tenosynovial Giant Cell Tumor (TGCT).
Our global Phase 3 MANEUVER study demonstrates the best-in-class profile of pimicotinib for treating Tenosynovial Giant Cell Tumor (TGCT).
Abbisko’s pimicotinib meets endpoints in phase III
bioworld.com
-
#TGCT#Global Phase III Trial#Positive Top-line Results
Positive Top-line Results from Pivotal Phase 3 MANEUVER Study of Pimicotinib in Patients with Tenosynovial Giant Cell Tumor
和誉医药，发布于领英
-
#EORTC-NCI-AACR##potential best-in-class PRMT5*MTA inhibitor
Abbisko presented preclinical research results of its PRMT5* MTA and oral KRASG12D programs at the 36th International Molecular Targets and Cancer Tre
和誉医药，发布于领英